Overview

Natrecor in Pulmonary Hypertension

Status:
Terminated
Trial end date:
2006-03-28
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the drug nesiritide (Natrecor) is effective in lowering the pressure in your lungs. The primary objective of this study is to establish that Nesiritide (Natrecor) is effective in reducing pulmonary hypertension (PHTN) acutely as measured by a 20% reduction in the mean pulmonary arterial (PA) pressure. The secondary objectives will include: improvement in pulmonary vascular resistance (PVR), patient symptoms, exercise tolerance, frequency of toxicity, and surgeon's willingness to proceed with operation.
Phase:
Phase 4
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Natriuretic Peptide, Brain